Key facts
- This page summarizes Fred B. Craves's Form 4 filing for MADRIGAL PHARMACEUTICALS, INC. (MDGL).
- 19 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 14 Mar 2025, 16:25.
Fred B. Craves - 12 Mar 2025 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)
- Reporting relationship
- Director
- Issuer ticker
- MDGL
- Reported as of
- 12 Mar 2025
- Net transaction value
- -$3,800,001
- SEC form
- 4
- Accepted by SEC
- 14 Mar 2025, 16:25:06 UTC
- Prior SEC filing
- 05 Dec 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mardi Dier, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Fred B. Craves filed Form 4 for MADRIGAL PHARMACEUTICALS, INC. (MDGL) on 14 Mar 2025.
Change
- Previous filing in this sequence was filed on 05 Dec 2024.
- Current net transaction value: -$3,800,001.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MDGL
transaction
Common Stock
Options Exercise
- Transaction value
- $112,424
- Shares
- +1,728
- Change %
- +0.49%
- Price
- $65.06
- Shares after
- 351,804
- Date
- 12 Mar 2025
- Ownership
- Direct
MDGL
transaction
Common Stock
Options Exercise
- Transaction value
- $666,360
- Shares
- +6,000
- Change %
- +1.7%
- Price
- $111.06
- Shares after
- 357,804
- Date
- 12 Mar 2025
- Ownership
- Direct
MDGL
transaction
Common Stock
Sale
- Transaction value
- $524,560
- Shares
- -1,587
- Change %
- -0.44%
- Price
- $330.54
- Shares after
- 356,217
- Date
- 12 Mar 2025
- Ownership
- Direct
- Footnotes
- F1
MDGL
transaction
Common Stock
Sale
- Transaction value
- $914,221
- Shares
- -2,759
- Change %
- -0.77%
- Price
- $331.36
- Shares after
- 353,458
- Date
- 12 Mar 2025
- Ownership
- Direct
- Footnotes
- F2
MDGL
transaction
Common Stock
Sale
- Transaction value
- $791,726
- Shares
- -2,382
- Change %
- -0.67%
- Price
- $332.38
- Shares after
- 351,076
- Date
- 12 Mar 2025
- Ownership
- Direct
- Footnotes
- F3
MDGL
transaction
Common Stock
Sale
- Transaction value
- $266,926
- Shares
- -800
- Change %
- -0.23%
- Price
- $333.66
- Shares after
- 350,276
- Date
- 12 Mar 2025
- Ownership
- Direct
- Footnotes
- F4
MDGL
transaction
Common Stock
Sale
- Transaction value
- $66,994
- Shares
- -200
- Change %
- -0.06%
- Price
- $334.97
- Shares after
- 350,076
- Date
- 12 Mar 2025
- Ownership
- Direct
- Footnotes
- F5
MDGL
transaction
Common Stock
Options Exercise
- Transaction value
- $503,695
- Shares
- +7,742
- Change %
- +2.2%
- Price
- $65.06
- Shares after
- 357,818
- Date
- 13 Mar 2025
- Ownership
- Direct
MDGL
transaction
Common Stock
Sale
- Transaction value
- $629,100
- Shares
- -1,951
- Change %
- -0.55%
- Price
- $322.45
- Shares after
- 355,867
- Date
- 13 Mar 2025
- Ownership
- Direct
- Footnotes
- F6
MDGL
transaction
Common Stock
Sale
- Transaction value
- $533,394
- Shares
- -1,649
- Change %
- -0.46%
- Price
- $323.47
- Shares after
- 354,218
- Date
- 13 Mar 2025
- Ownership
- Direct
- Footnotes
- F7
MDGL
transaction
Common Stock
Sale
- Transaction value
- $292,218
- Shares
- -900
- Change %
- -0.25%
- Price
- $324.69
- Shares after
- 353,318
- Date
- 13 Mar 2025
- Ownership
- Direct
- Footnotes
- F8
MDGL
transaction
Common Stock
Sale
- Transaction value
- $260,501
- Shares
- -800
- Change %
- -0.23%
- Price
- $325.63
- Shares after
- 352,518
- Date
- 13 Mar 2025
- Ownership
- Direct
- Footnotes
- F9
MDGL
transaction
Common Stock
Sale
- Transaction value
- $327,627
- Shares
- -1,000
- Change %
- -0.28%
- Price
- $327.63
- Shares after
- 351,518
- Date
- 13 Mar 2025
- Ownership
- Direct
- Footnotes
- F10
MDGL
transaction
Common Stock
Sale
- Transaction value
- $131,472
- Shares
- -400
- Change %
- -0.11%
- Price
- $328.68
- Shares after
- 351,118
- Date
- 13 Mar 2025
- Ownership
- Direct
- Footnotes
- F11
MDGL
transaction
Common Stock
Sale
- Transaction value
- $318,975
- Shares
- -967
- Change %
- -0.28%
- Price
- $329.86
- Shares after
- 350,151
- Date
- 13 Mar 2025
- Ownership
- Direct
- Footnotes
- F12
MDGL
transaction
Common Stock
Sale
- Transaction value
- $24,767
- Shares
- -75
- Change %
- -0.02%
- Price
- $330.22
- Shares after
- 350,076
- Date
- 13 Mar 2025
- Ownership
- Direct
MDGL
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 11,210
- Date
- 12 Mar 2025
- Ownership
- See Footnote
- Footnotes
- F13
MDGL
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,261
- Date
- 12 Mar 2025
- Ownership
- See Footnotes
- Footnotes
- F14
MDGL
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 21,000
- Date
- 12 Mar 2025
- Ownership
- See Footnotes
- Footnotes
- F15
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MDGL
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -1,728
- Change %
- -18%
- Price
- $0.000000
- Shares after
- 7,742
- Date
- 12 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,728
- Exercise price
- $65.06
- Footnotes
- F16
MDGL
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -6,000
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 12 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,000
- Exercise price
- $111.06
- Footnotes
- F16
MDGL
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -7,742
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 13 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,742
- Exercise price
- $65.06
- Footnotes
- F16
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 16 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $330.00 to $330.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $331.00 to $331.89, inclusive.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $332.01 to $332.88, inclusive.
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $333.39 to $333.89, inclusive.
Footnote F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $334.95 to $334.99, inclusive.
Footnote F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $322.02 to $323.00, inclusive.
Footnote F7
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $323.02 to $323.97, inclusive.
Footnote F8
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $324.16 to $324.84, inclusive.
Footnote F9
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $325.34 to $325.955, inclusive.
Footnote F10
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $327.19 to $328.18, inclusive.
Footnote F11
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $328.20 to $329.165, inclusive.
Footnote F12
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $329.22 to $330.20, inclusive.
Footnote F13
Represents shares held indirectly by Dr. Craves through a grantor retained annuity trust.
Footnote F14
These securities are held by Bay City Capital LLC ("BCC"). Dr. Craves disclaims beneficial ownership of these securities held by BCC, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.
Footnote F15
Represents shares held indirectly by Dr. Craves through the Craves Family Foundation.
Footnote F16
The shares underlying this stock option are fully vested and exercisable.